Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab
https://doi.org/10.14412/1995-4484-2009-452
Abstract
Objective. To reveal changes of CD+CD25+FoxP3+ T-regulatory cells (T-reg) number in pts with systemic lupus erythematosus (SLE) receiving rituximab and to assess relationship T reg content with changes of disease activity and serum autoantibodies level during treatment. Material and methods. 12 pts with definite SLE were included. Pts were examined before treatment, after 1, 3 and 6 months. Besides routine laboratory tests anti-double-stranded DNA antibodies, B lymphocytes and T reg cells number was evaluated with flow-cytometry. SLE activity was assessed with SLEDAI 2K scale. Rituximab 500 mg was administered every week iv during 4 weeks. 4 pts received combined treatment with cyclophosphan. Results. Mean age of pts was 30,5±9,8 years (Me 31 years, varied from 18 to 49 years), disease duration varied from 7 to 148 months. T reg number before treatment was not decreased and did not correlated with anti-DNA antibodies level. T reg markers (Foxp3+, CD25+, CD4+CD25+) changes and values of SLE activity on SLEDAI 2K after the end of treatment correlated with presence of clinical response to treatment with rituximab in 3 months. Binary logistic regression model including 4 above mentioned predictors in total allows predicting correctly clinical response to therapy in 83% of cases. Conclusion. Changes of CD25+, CD4+CD25+, CD4+CD25+FoxP3+ T-cells number immediately after the end of treatment with rituximab correlated with clinical effect of the treatment and determined subsequent response to anti-B cell therapy.
References
1. <div><p>Tsokos G.C.,Wong H.K., Enyedy E.J. et al. Immune cell signaling in lupus. Curr. Opin. Rheumatol, 2000, 12, 355–63.</p><p>Shevach E.M., McHugh R.S., Piccirillo C.A., Thornton A.M. Control of T-cell activation by CD4+ CD25+ sup- pressor T cells. Immunol Rev, 2001,182,58-67.</p><p>Hall B.M., Pearce N.W., Gurley K.E. et al. Specific unresponsiveness in rats with prolonged cardiac allograft after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J. Exp. Med., 1990, 171,141- 57.</p><p>Sakaguchi S., Sakaguchi N., Asano M. et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol., 1995, 155, 1151-64.</p><p>Bluestone J.A., Abbas A.K., Natural versus adap- tive regulatory T cells. Nat. Rev. Immunol., 2003, 3, 253–57.</p><p>Piccirillo C.A., Thornton A.M. Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells. Trends Immunol., 2004, 25, 374–80.</p><p>Von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat. Immunol., 2005, 6, 338–44.</p><p>Thompson C.B., Allison J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity, 1997, 7, 445-50.</p><p>Grossman W.J., Verbsky J.W., Barchet W. et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity, 2004, 21, 589-601.</p><p>Dieckmann D., Bruett C.H., Ploettner H. et al. Human CD4+CD25+ regulatory, contact-dependent T cells induce IL-10 producing, contact-independent type 1-like regulatory T cells. J. Exp. Med., 2002, 196, 247-53.</p><p>Thornton A.M., Shevach E.M. CD4+CD25+ immuno- regulatory T cells suppress polyclonal T-cell activation in vitro by inhibiting interleukin-2 production. J. Exp. Med., 1998, 188, 287–96.</p><p>Baecher-Allan C., Brown J.A., Freeman G.J. et al. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol., 2001, 167(3), 1245-53.</p><p>Fontenot J.D., Gavin M.A., Rudensky A.Y., Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol., 2003, 4(4), 330-6.</p><p>Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science, 2003, 299(5609), 1057-61.</p><p>Bennett C.L., Christie J., Ramsdell F. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet., 2001, 27(1), 20-1.</p><p>Wolf D., Hochegger K., Wolf A.M. et al. CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice, J. Am. Soc. Nephrol., 16, 2005, 1360–70.</p><p>Liu M.F., Wang C.R., Fung L.L. et al. Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand. J. Immunol., 2004, 59, 198–202.</p><p>Crispin J.C., Martinez A., Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun., 2003, 21, 273–6.</p><p>Miyara M., Amoura Z., Parizot C. et al. Global natu- 8 ral regulatory T cell depletion in active systemic lupus erythematosus. J. Immunol., 2005, 175, 8392–400.</p><p>Alvarado-Sanchez B., Hernandez-Castro B., Portales- Perez D. et al. Regulatory T cells in patients with sys- temic lupus erythematosus. J. Autoimmun., 2006, 27, 110-8.</p><p>Suarez A., Lopez P., Gomez J. et al. Enrichment of CD4+CD25high T cell population in SLE patients treated with glucocorticoids. Ann. Rheum. Dis., 2006, 65(11), 1512-7.</p><p>Hochberg M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematotosus. Arthr. Rheum., 1997,40, 1725.</p><p>Vitali C., Bencivelli W., Isenberg D. A. et al. Disease activity in SLE: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin. Exp. Rheumatol., 1992,10, 541-47.</p><p>Vallerskog T., Gunnarsson I., Widhe M. et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin. Immun., 2007, 122, 62-74.</p><p>Sfikakis P.P., Boletis J.N., Lionaki S. et al. Remission of proliferative lupus nephritis following B cell deple- tion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum., 2005, 52, 501–13.</p><p>Sfikakis P.P., Souliotis V.L., Fragiadaki K.G. et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immun., 2007, 123, 66-73.</p><p>Vigna-Perez M., Hernandez-Castro B., Paredes-Saharopulos O. et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther., 2006, 8, R83.</p><p>Douek D.C., Vescio R.A., Betts M.R. et al. Assessment of thymic output in adults after hematopoietic stem cell transplantation and prediction of T-cell reconstitution. Lancet, 2000, 355, 1875–81.</p><p>Pawelec G., Barnett Y., Forsey R. et al. Tcells and aging. Front. Biosci., 2002, 7, 1056–183.</p><p>Sfikakis P.P., Gourgoulis G.M., Moulopoulos L.A. et al. Age-related thymic activity in adults following chemotherapy-induced lymphopenia. Eur. J. Clin. Invest., 2005, 35, 380–7.</p><p>Tone M., Tone Y., Adams E. et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc. Natl. Acad. Sci. USA, 2003, 100, 15059-64.</p><p>Shevach E.M. Regulatory/suppressor T cells in health and disease. Arthritis Rheum., 2004, 50, 2721-4.</p><p>Ehrenstein M.R., Evans J.G., Singh A. et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-alpha therapy. J. Exp. Med., 2004, 200, 277-85.</p><p>Monk C.R., Spachidou M., Rovis F. et al. MRL/Mp CD4+, CD25- T cells show reduced sensitivity to suppression by CD4+CD25+ regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus. Arthritis Rheum., 2005, 52, 1180-4.</p><p>Wohlfert E.A., Gorelik L., Mittler R. et al. Deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunc- tional defect in T cell TGF-β sensitivity in vitro and in vivo. J. Immunol., 2006, 176, 1316-20.</p><p>Leandro M.J., Cambridge G., Edwards J.C. et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology, 2005, 44, 1542-5.</p><p>Albert D., Dunham J., Khan S. et al. Variability in the biological response to anti-CD20 B-cell depletion in SLE. Ann. Rheum. Dis., 2008, 67(12),1724-31.</p><p>Cambridge G., Leandro M.J., Teodorescu M. et al. B Cell Depletion therapy in systemic lupus erythematosus, effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum., 2006, 11, 3612-22.</p><p>Tokunaga M., Saito K., Kawabata D. et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis., 2007, 66, 470–5.</p><p>Looney R.J., Anolik J.H., Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum., 2004, 50, 2580–9</p></div><br />
Review
For citations:
Torgashina A.V. Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab. Rheumatology Science and Practice. 2009;47(2):3-9. (In Russ.) https://doi.org/10.14412/1995-4484-2009-452
Views:
746
Email this article 